CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 393 enrolled
Drug / intervention
Methoxy polyethylene glycol-epoetin betadrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02547454
NCT02547454N/ACompleted
CompareCT.gov

Investigating the Effectiveness of Renal Anaemia Treatment in Pre-Dialysis Patients With Mircera in Daily Clinical Practice - MIRVITA

Hoffmann-La Roche·observational·Posted Sep 11, 2015·Updated Jun 7, 2017

In Brief

An observational study evaluating Methoxy polyethylene glycol-epoetin beta for Kidney Disease, Chronic. Completed, enrolled 393 participants across 12 sites.

Detailed Summary

This observational trial will examine the efficacy and safety of Mircera for renal anemia in participants with stage III-IV CKD in daily clinical practice. Mircera will be prescribed by treating physician and followed for approximately 36 months.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsKidney Disease, Chronic
CountriesSlovenia
Collaborators--

Timeline

N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedSep 11, 2015
Enrollment StartDec 31, 2008
Primary CompletionNov 30, 2014
TodayJul 2, 2026
Enrollment to primary: 5.9 yearsPosted 10.8 years ago

Interventions

Methoxy polyethylene glycol-epoetin betadrug